<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110325006105N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-08</date_registration>
      <primary_sponsor>Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>Different Aspects of Two Adjacent Primary Molars Treatment</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of Physiologic and non physiologic  Effects of Two Adjacent Primary Molars Treatment in One Single Session in5-7 years old children</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>58</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74633</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Crossover, Purpose: Supportive, Other design features: A split-mouth design is used to investigate the effect of treating two adjacent teeth on the variables. Two molars on the experimental side and one molar on the control side are treated. All children in the pediatric department are treated by two dental resident under the supervision of a pediatric specialist. For each participant, both sides of the jaw will be treated by a single operator in two separate consecutive sessions with a two-week interval between the treatment sessions. This time interval between sessions is planned to eliminate the effects of the first encounter on the outcomes of the second encounter. Additionally, to eliminate any unknown treatment effect from the first session to the second session, children will be randomly divided into two groups using a random block method. One group will receive single-tooth pulpotomy treatment and stainless steel crown (SSC) initially, while the other group will receive pulpotomy treatment for the adjacent molars and SSC in one session initially. Furthermore, depending on which dental arch (right or left) will receive the first treatment, two subgroups from each of the initial groups will be extracted using a random block method. For both sides, treatments are performed as a single session of complete treatment, Randomization description: Allocation of samples will be done using quadruple blocks, where half of the individuals are assigned to group one and the other half to group two. All possible quadruple scenarios are as follows:
Where 'A' belongs to group one and 'B' belongs to group two.

1. A A B B
2. A B A B
3. A B B A
4. B B A A
5. B A B A
6. B A A B

In the next step, each of these quadruple combinations will be assigned a number from 1 to 6. Following that, approximately 15 random quadruple blocks will be selected based on the total sample size and the sample size for each group. The order of these selected blocks will be determined, and the allocation of individuals to groups one and two will be based on these chosen orders. By continuing this process, we ensure that the difference between the two groups will not exceed two individuals at most, Blinding description: The assessor of the physiological and non-physiological measures is currently blinded to which side (adjacent treatment of two decayed primary molars in one session under the experimental group and treatment of one decayed primary molar in one session under the control group) is being performed.
The participant is unaware of how to check the sequence of sessions.</study_design>
      <phase>N/A</phase>
      <hc_freetext>pulpotomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention side: Prior to injection, local gel will be used at the injection site. A volume of 1.8 milliliters of 2% lidocaine with 1/80000 epinephrine solution at room temperature will be slowly administered using a regular syringe (1 milliliter per minute, only one cartridge). For anesthesia of the upper and lower jaw, participants will receive infiltration and inferior alveolar nerve block sequentially using a 21-gauge needle with a 27-gauge and 35-gauge needle with a 27-gauge respectively. Intrapapillary anesthesia will be performed for complete anesthesia. After 15 minutes have elapsed since the administration of anesthesia, treatment will begin. All dental procedures will be performed using rubber dam isolation. After performing pulp treatment, the adjacent tooth will be restored using light-cured glass ionomer cement for crown restoration. Then, SSCs will be adjusted and cemented using glass ionomer cement. Intervention 2: Control side: Intervention Group 1: Before injection, local gel will be used at the injection site. A volume of 1.8 milliliters of 2% lidocaine with 1/80000 epinephrine solution at room temperature will be slowly administered using a regular syringe (1 milliliter per minute, only one cartridge). For anesthesia of the upper and lower jaw, participants will receive infiltration and inferior alveolar nerve block sequentially using a 21-gauge needle with a 27-gauge and 35-gauge needle with a 27-gauge respectively. Intrapapillary anesthesia will be performed for complete anesthesia. After 15 minutes have elapsed since the administration of anesthesia, treatment will begin. All dental procedures will be performed using rubber dam isolation. After performing pulp treatment, a primary molar tooth will be restored using light-cured glass ionomer cement for crown restoration. Then, SSCs will be adjusted and cemented using glass ionomer cement.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
information about the main outcome and its comparison with different groups can be shared.

When:
Access period starts 6 months after the results are published.

To whom:
Researchers working in academic and scientific institutes, dental students, dentists.

Conditions:
The ultimate goals are providing adequate dental services, creating a good experience, consolidating good communication between the individual child and dental team and avoiding any fear and anxiety throughout future life and improve treatment results. all dental researchers will be able to access the data.

Where to obtain:
Dr.nahid ramazani
ramazani77@gmail.com
+989155009085

How to obtain:
please send an email to the respondent and state the resume and purpose of accessing the data for the respondent.The respondent will respond to the initial email within a week, and if documents need to be sent, the documents will be sent to the applicant within a month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nahid Ramazani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zahedan, East Azadegan St, School of dentistry</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9817699693</zip>
        <telephone>+98 54 3344 1814</telephone>
        <email>ramazani77@gmail.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>ٔNahid Ramazani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zahedan, East Azadegan St, School of dentistry</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9817699693</zip>
        <telephone>+98 54 3344 1824</telephone>
        <email>ramazani77@gmail.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children aged 7-5 years without any physical or mental illnesses
Cooperative based on the Frankl behavior rating scale (Frankl 3 or 4)
Candidates for routine treatment for the first time (no previous treatment history)
Having a minimum of four asymptomatic decayed primary molars requiring pulpotomy and SSC
Requiring a minimum of three consecutive treatment sessions to treat all decayed teeth</inclusion_criteria>
      <agemin>5 years</agemin>
      <agemax>7 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Children with a history of unfavorable medical or dental conditions
Tooth pain, except for food impaction
Systemic illness or medication intake
Any known allergies or contraindications to anesthesia drugs
Non-cooperative children (Frankl 1)
Deciduous teeth without succedaneous tooth buds</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention side: Prior to injection, local gel will be used at the injection site. A volume of 1.8 milliliters of 2% lidocaine with 1/80000 epinephrine solution at room temperature will be slowly administered using a regular syringe (1 milliliter per minute, only one cartridge). For anesthesia of the upper and lower jaw, participants will receive infiltration and inferior alveolar nerve block sequentially using a 21-gauge needle with a 27-gauge and 35-gauge needle with a 27-gauge respectively. Intrapapillary anesthesia will be performed for complete anesthesia. After 15 minutes have elapsed since the administration of anesthesia, treatment will begin. All dental procedures will be performed using rubber dam isolation. After performing pulp treatment, the adjacent tooth will be restored using light-cured glass ionomer cement for crown restoration. Then, SSCs will be adjusted and cemented using glass ionomer cement</i_keyword>
      <i_keyword>Control side: Intervention Group 1: Before injection, local gel will be used at the injection site. A volume of 1.8 milliliters of 2% lidocaine with 1/80000 epinephrine solution at room temperature will be slowly administered using a regular syringe (1 milliliter per minute, only one cartridge). For anesthesia of the upper and lower jaw, participants will receive infiltration and inferior alveolar nerve block sequentially using a 21-gauge needle with a 27-gauge and 35-gauge needle with a 27-gauge respectively. Intrapapillary anesthesia will be performed for complete anesthesia. After 15 minutes have elapsed since the administration of anesthesia, treatment will begin. All dental procedures will be performed using rubber dam isolation. After performing pulp treatment, a primary molar tooth will be restored using light-cured glass ionomer cement for crown restoration. Then, SSCs will be adjusted and cemented using glass ionomer cement</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Average systolic blood pressure. blood pressure, average diastolic blood pressure. Timepoint: in three separate times (time of completion of anesthesia administration, in the middle of the treatment and in the final moments of the treatment). Method of measurement: "Systolic blood pressure" using "digital instrument with wrist cuff  Diastolic blood pressure" using ""digital instrument with wrist cuff.</prim_outcome>
      <prim_outcome>Average heart rate. Timepoint: In three separate times (time of completion of anesthesia administration, in the middle of the treatment and in the final moments of the treatment). Method of measurement: "heart rate" using "digital instrument with wrist cuff.</prim_outcome>
      <prim_outcome>Average oxygen saturation. Timepoint: In three separate times (time of completion of anesthesia administration, in the middle of the treatment and in the final moments of the treatment). Method of measurement: "oxygen saturation" using "pulse oximeter".</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of treatment. Timepoint: The duration of the treatment is at the end of the treatment. Method of measurement: Treatment duration using cornometer.</sec_outcome>
      <sec_outcome>The average number of consumed painkillers. Timepoint: The dose numbers of analgesic by asking the parents in the days after the treatment. Method of measurement: The dose numbers of analgesic by asking the parents in the days after the treatment.</sec_outcome>
      <sec_outcome>The average behavior score. Timepoint: Average discomfort upon completion of treatment. Method of measurement: Frankle behavior rating scale.</sec_outcome>
      <sec_outcome>The average discomfort level. Timepoint: Average discomfort upon completion of treatment. Method of measurement: Facial image score.</sec_outcome>
      <sec_outcome>The average post-treatment pain. Timepoint: Average post-treatment pain as soon as the treatment is completed. Method of measurement: Wong baker faces pain.</sec_outcome>
      <sec_outcome>The average parental satisfaction                                                                 . Timepoint: Parental consent upon completion of treatment. Method of measurement: parental satisfaction based on a five-point response.</sec_outcome>
      <sec_outcome>Next appointment refusal. Timepoint: apposition to meeting at the beginning of the second and third session. Method of measurement: refusal for the second and third session appointments based on the child's report.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-27</approval_date>
        <contact_name>Ethics committee of Zahedan University of Medical Sciences</contact_name>
        <contact_address>Zahedan, Persian Gulf Blvd., College, resistance Research and Technology Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
